Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.
作者信息
Porta C
出版信息
Br J Cancer. 2010 Mar 30;102(7):1196-7. doi: 10.1038/sj.bjc.6605585. Epub 2010 Feb 23.
Abstract
摘要
相似文献
1
Regarding: 'Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib'.关于：“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合α-干扰素2a与舒尼替尼的比较”
Br J Cancer. 2010 Mar 30;102(7):1196-7. doi: 10.1038/sj.bjc.6605585. Epub 2010 Feb 23.
2
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.对“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合干扰素-α2a与舒尼替尼的比较”的评论
Br J Cancer. 2010 Oct 12;103(8):1307-8; author reply 1309-10. doi: 10.1038/sj.bjc.6605886. Epub 2010 Sep 14.
3
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.一线转移性肾细胞癌治疗中不良反应管理成本：贝伐珠单抗联合干扰素-α2a 与舒尼替尼比较。
Br J Cancer. 2010 Jan 5;102(1):80-6. doi: 10.1038/sj.bjc.6605417. Epub 2009 Nov 17.
4
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysis.贝伐珠单抗联合干扰素-α对比舒尼替尼用于意大利肾细胞癌一线治疗的成本最小化分析。
Clin Drug Investig. 2011;31(7):507-17. doi: 10.2165/11590230-000000000-00000.
5
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.贝伐珠单抗、索拉非尼甲苯磺酸盐、舒尼替尼和替西罗莫司治疗肾细胞癌：系统评价和经济评估。
Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. doi: 10.3310/hta14020.
6
Tolerability of first-line therapy for metastatic renal cell carcinoma.转移性肾细胞癌一线治疗的耐受性
Cancer Treat Rev. 2009 May;35(3):297-307. doi: 10.1016/j.ctrv.2008.12.003. Epub 2009 Feb 26.
7
Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness.舒尼替尼和贝伐单抗用于转移性肾细胞癌一线治疗：临床疗效的系统评价和间接比较
Br J Cancer. 2009 Jul 21;101(2):238-43. doi: 10.1038/sj.bjc.6605167. Epub 2009 Jun 30.
8
Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.用于肾细胞癌的新型药物需要新型选择模式来优化一线治疗。
Cancer Treat Rev. 2009 May;35(3):289-96. doi: 10.1016/j.ctrv.2009.01.004. Epub 2009 Feb 15.
9
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.转移性肾细胞癌的靶向治疗：毒性及给药策略概述
Oncologist. 2008 Oct;13(10):1084-96. doi: 10.1634/theoncologist.2008-0120. Epub 2008 Oct 6.
10
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.初治晚期/转移性肾细胞癌患者的一线治疗：已发表随机对照试验的系统评价
Anticancer Drugs. 2016 Jun;27(5):383-97. doi: 10.1097/CAD.0000000000000335.
引用本文的文献
1
Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.对“一线转移性肾细胞癌治疗中不良事件管理的成本：贝伐单抗联合干扰素-α2a与舒尼替尼的比较”的评论
Br J Cancer. 2010 Oct 12;103(8):1307-8; author reply 1309-10. doi: 10.1038/sj.bjc.6605886. Epub 2010 Sep 14.
本文引用的文献
1
Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.一线转移性肾细胞癌治疗中不良反应管理成本：贝伐珠单抗联合干扰素-α2a 与舒尼替尼比较。
Br J Cancer. 2010 Jan 5;102(1):80-6. doi: 10.1038/sj.bjc.6605417. Epub 2009 Nov 17.
2
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.舒尼替尼治疗转移性肾细胞癌后的心血管毒性：一项多中心分析。
Ann Oncol. 2009 Sep;20(9):1535-1542. doi: 10.1093/annonc/mdp025. Epub 2009 May 27.
3
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.新型靶向抗癌疗法诱发的心脏功能障碍：一个新出现的问题。
Curr Cardiol Rep. 2009 May;11(3):167-74. doi: 10.1007/s11886-009-0025-9.
4
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.与酪氨酸激酶抑制剂相关的甲状腺功能减退：靶向治疗的一种新出现的毒性作用。
Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4.
5
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma.一线使用贝伐单抗联合减量的α-干扰素2a对转移性肾细胞癌患者有效。
Ann Oncol. 2008 Aug;19(8):1470-1476. doi: 10.1093/annonc/mdn161. Epub 2008 Apr 11.
6
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.贝伐单抗联合干扰素α-2a治疗转移性肾细胞癌：一项随机、双盲III期试验。
Lancet. 2007 Dec 22;370(9605):2103-11. doi: 10.1016/S0140-6736(07)61904-7.
7
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.舒尼替尼与干扰素α治疗转移性肾细胞癌的对比研究
N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.
8
Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.舒尼替尼治疗的转移性肾细胞癌患者中的甲状腺功能减退症
J Natl Cancer Inst. 2007 Jan 3;99(1):81-3. doi: 10.1093/jnci/djk008.
Zotero 插件